Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen

Inclusion Criteria: * A male or female infant between 6 and 10 weeks of age at the time of first vaccination. * Signed or thumb-printed informed consent obtained from the parent(s)/guardian(s) of the child. Where parent(s)/guardian(s) are illiterate, the consent form will be countersigned by a witness. * Subjects who have received one previous dose of OPV and BCG. * Subjects who are born after a normal gestation period (between 36 and 42 weeks). Exclusion Criteria: * Acute disease at the time of enrolment. * Serious acute or chronic illness determined by clinical or physical examination and laboratory screening tests. * Laboratory screening tests out of range, specifically: ALT and creatinine above acceptable limit; Hemoglobin, Platelet count and Total white cell count below acceptable limit. * Previous vaccination with diphtheria, tetanus, pertussis (whole-cell or acellular), Hemophilus influenzae type b or hepatitis B vaccines. * BCG administration within one week of proposed administration of a study vaccine. * OPV administration within four weeks of proposed administration of a study vaccine. * Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine(s). * Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Administration of immunoglobulins, blood transfusions or other blood products since …